The rise of Sildenafil initially sparked a boom for major pharmaceutical companies, but recent changes present a murky picture for shareholders. Generic alternatives are eroding earnings, and persistent legal battles https://tedhudy145450.newbigblog.com/48086140/the-blue-pill-and-big-pharma-a-volatile-bet